GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Axsome Therapeutics Inc (STU:19X) » Definitions » Cyclically Adjusted PB Ratio

Axsome Therapeutics (STU:19X) Cyclically Adjusted PB Ratio : 47.64 (As of Jan. 19, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Axsome Therapeutics Cyclically Adjusted PB Ratio?

As of today (2025-01-19), Axsome Therapeutics's current share price is €90.52. Axsome Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2024 was €1.90. Axsome Therapeutics's Cyclically Adjusted PB Ratio for today is 47.64.

The historical rank and industry rank for Axsome Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

STU:19X' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 32.03   Med: 40.65   Max: 48.45
Current: 43.07

During the past years, Axsome Therapeutics's highest Cyclically Adjusted PB Ratio was 48.45. The lowest was 32.03. And the median was 40.65.

STU:19X's Cyclically Adjusted PB Ratio is ranked worse than
98.82% of 595 companies
in the Biotechnology industry
Industry Median: 1.57 vs STU:19X: 43.07

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Axsome Therapeutics's adjusted book value per share data for the three months ended in Sep. 2024 was €1.728. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €1.90 for the trailing ten years ended in Sep. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Axsome Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Axsome Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Axsome Therapeutics Cyclically Adjusted PB Ratio Chart

Axsome Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 39.89

Axsome Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 39.89 37.65 37.75 42.11

Competitive Comparison of Axsome Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Axsome Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Axsome Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Axsome Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Axsome Therapeutics's Cyclically Adjusted PB Ratio falls into.



Axsome Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Axsome Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=90.52/1.9
=47.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Axsome Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2024 is calculated as:

For example, Axsome Therapeutics's adjusted Book Value per Share data for the three months ended in Sep. 2024 was:

Adj_Book=Book Value per Share/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=1.728/133.0289*133.0289
=1.728

Current CPI (Sep. 2024) = 133.0289.

Axsome Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201412 -0.204 99.070 -0.274
201503 0.000 99.621 0.000
201506 -0.363 100.684 -0.480
201509 0.196 100.392 0.260
201512 2.226 99.792 2.967
201603 1.934 100.470 2.561
201606 1.622 101.688 2.122
201609 1.311 101.861 1.712
201612 1.067 101.863 1.393
201703 1.163 102.862 1.504
201706 0.858 103.349 1.104
201709 0.597 104.136 0.763
201712 0.554 104.011 0.709
201803 0.399 105.290 0.504
201806 0.229 106.317 0.287
201809 0.024 106.507 0.030
201812 0.027 105.998 0.034
201903 0.462 107.251 0.573
201906 0.626 108.070 0.771
201909 0.180 108.329 0.221
201912 4.355 108.420 5.343
202003 3.812 108.902 4.657
202006 3.675 108.767 4.495
202009 3.075 109.815 3.725
202012 2.503 109.897 3.030
202103 2.153 111.754 2.563
202106 1.575 114.631 1.828
202109 0.963 115.734 1.107
202112 0.366 117.630 0.414
202203 0.343 121.301 0.376
202206 0.360 125.017 0.383
202209 3.660 125.227 3.888
202212 2.378 125.222 2.526
202303 2.398 127.348 2.505
202306 5.525 128.729 5.710
202309 5.337 129.860 5.467
202312 3.698 129.419 3.801
202403 2.792 131.776 2.819
202406 1.999 132.554 2.006
202409 1.728 133.029 1.728

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Axsome Therapeutics  (STU:19X) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Axsome Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Axsome Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Axsome Therapeutics Business Description

Traded in Other Exchanges
Address
One World Trade Center, 22nd Floor, New York, NY, USA, 10007
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

Axsome Therapeutics Headlines

No Headlines